Attached files
file | filename |
---|---|
8-K - LIVE FILING - IMMUNE PHARMACEUTICALS INC | htm_44091.htm |
EX-99.1 - EX-99.1 - IMMUNE PHARMACEUTICALS INC | exhibit1.htm |
Contacts
EpiCept Corporation: | Investors: | |
777 Old Saw Mill River Road | LHA | |
Tarrytown, NY 10591 | Kim Sutton Golodetz | |
Robert W. Cook | (212) 838-3777 | |
(914) 606-3500 | kgolodetz@lhai.com | |
rcook@epicept.com | ||
or | ||
Bruce Voss | ||
(310) 691-7100 | ||
bvoss@lhai.com | ||
Media:
|
||
Feinstein Kean Healthcare Greg Kelley (617) 577-8110 gregory.kelley@fkhealth.com |
||
EpiCept Corporation Confirms Engagement of SunTrust Robinson Humphrey to Include
Evaluation of Potential Sale Transactions
TARRYTOWN, N.Y. (January 24, 2012) EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today confirmed that its engagement of SunTrust Robinson Humphrey to assist in exploring strategic alternatives to maximize the commercial opportunity of AmiKet includes the evaluation of potential transactions involving the sale of the Company. AmiKet is the Companys prescription topical cream intended for the treatment of neuropathic pain. The engagement of SunTrust Robinson Humphrey will focus on the identification and implementation of a strategy designed to optimize AmiKets value for the Companys shareholders.
In an article dated January 24, 2012 appearing in Nyhetsbyrån Direkt (Stockholm, Sweden), Jack Talley, EpiCepts President and CEO, indicated that in addition to exploring strategic alternatives, the Company would consider a sale at a reasonable price.
EpiCept recently announced that it has received further encouraging guidance for the Phase III clinical and nonclinical development and subsequent New Drug Application (NDA) filing of AmiKet in the treatment of chemotherapy-induced peripheral neuropathy (CIPN) based on the issuance of the final minutes of the Companys meeting with the U.S. Food and Drug Administration (FDA) in December 2011.
About AmiKet
AmiKet is a prescription, topical analgesic cream containing 4% amitriptyline and 2% ketamine
designed to provide relief from neuropathic pain, which affects more than 15 million people in the
U.S. alone. In the first half of 2011, EpiCept announced positive results from a National Cancer
Institute-sponsored study evaluating the efficacy and safety of AmiKet in CIPN, a painful
condition that frequently occurs following systemic chemotherapy and that may interrupt, delay or
even prevent completion of potentially curative chemotherapy regimens. A safe and effective
therapeutic option for neuropathic pain associated with CIPN would address a significant unmet
medical need.
About EpiCept Corporation
EpiCept is focused on the development and commercialization of pharmaceutical products for the
treatment of cancer and pain. The Companys pain portfolio includes AmiKet, a prescription topical
analgesic cream in late-stage clinical development designed to provide effective long-term relief
of pain associated with peripheral neuropathies. The Companys lead oncology product is
Ceplene®, which has been granted full marketing authorization by the European Commission
for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid
Leukemia (AML) in first remission. The Company has other oncology drug candidates currently in
clinical development that were discovered using in-house technology and have been shown to act as
vascular disruption agents in a variety of solid tumors.
Forward-Looking Statements
This news release and any oral statements made with respect to the information contained in this
news release contain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements include statements which express
plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not
statements of historical fact. These statements are based on our current expectations and are
subject to risks and uncertainties that could cause actual results or developments to be materially
different from historical results or from any future results expressed or implied by such
forward-looking statements. Factors that may cause actual results or developments to differ
materially include: the risk that Ceplene® will not receive regulatory approval or
marketing authorization in the United States or Canada, the risk that Ceplene® will not
achieve significant commercial success, the risk that any required post-approval clinical study for
Ceplene® will not be successful, the risk that we will not be able to maintain our final
regulatory approval or marketing authorization for Ceplene®, the risks associated with
the adequacy of our existing cash resources and our ability to continue as a going concern, the
risks associated with our ability to continue to meet our obligations under our existing debt
agreements, the risk that Azixa will not receive regulatory approval or achieve significant
commercial success, the risk that we will not receive any significant payments under our agreement
with Myrexis, the risk that the development of our other apoptosis product candidates will not be
successful, the risk that clinical trials for AmiKet or crolibulinTM will not be
successful, the risk that AmiKet or crolibulinTM will not receive regulatory approval
or achieve significant commercial success, the risk that we will not be able to find a partner to
help conduct the Phase III trials for AmiKet on attractive terms, a timely basis or at all, the
risk that our other product candidates that appeared promising in early research and clinical
trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials,
the risk that we will not obtain approval to market any of our product candidates, the risks
associated with dependence upon key personnel, the risks associated with reliance on collaborative
partners and others for further clinical trials, development, manufacturing and commercialization
of our product candidates; the cost, delays and uncertainties associated with our scientific
research, product development, clinical trials and regulatory approval process; our history of
operating losses since our inception; the highly competitive nature of our business; risks
associated with litigation; and risks associated with our ability to protect our intellectual
property. These factors and other material risks are more fully discussed in our periodic reports,
including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and
Exchange Commission. You are urged to carefully review and consider the disclosures found in our
filings which are available at www.sec.gov or at www.epicept.com. You are cautioned
not to place undue reliance on any forward-looking statements, any of which could turn out to be
wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.
*Azixa is a registered trademark of Myrexis, Inc.
# # #
EPCT-GEN